deltatrials
Completed PHASE2 NCT00080223

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Sponsor: Genentech, Inc.

Conditions Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis
Interventions Pirfenidone
Updated 8 times since 2017 Last updated: Mar 20, 2017 Started: Aug 31, 2003 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This PHASE2 trial investigates Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis and is currently completed. Genentech, Inc. leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2017 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annandale, United States, Atlanta, United States, Boston, United States, Bremerton, United States, Dallas, United States, Elk Grove Village, United States, Houston, United States, Huntington Station, United States, Kailua, United States, Lahaina, United States and 15 more location s